FDA seeks to remove warnings from labels of hormone therapies for menopausenews2025-11-10T20:21:16+00:00November 10th, 2025|Endpoints News|
#AHA25: Novo Nordisk posts mixed mid-stage data on ATTR-CM drugnews2025-11-10T20:00:37+00:00November 10th, 2025|Endpoints News|
Cogent soars on back of Phase 3 success in stromal tumorsnews2025-11-10T16:30:46+00:00November 10th, 2025|Endpoints News|
AnaptysBio reports Phase 2 fail in ulcerative colitis; Lyell’s CAR-T licensing dealnews2025-11-10T16:14:00+00:00November 10th, 2025|Endpoints News|
In string of deals, Lilly nabs ultra rare eye disease gene therapy and RNAi partnernews2025-11-10T16:00:46+00:00November 10th, 2025|Endpoints News|
#AHA25: CRISPR Therapeutics’ gene editing therapy halves cholesterol and triglycerides in early trialnews2025-11-10T15:25:01+00:00November 10th, 2025|Endpoints News|
Catalent lays off more gene therapy workers in Baltimorenews2025-11-10T14:13:30+00:00November 10th, 2025|Endpoints News|
Ex-Lilly Diabetes leaders hunt for new obesity drugs at VC firmnews2025-11-10T14:00:26+00:00November 10th, 2025|Endpoints News|
Roche reports two Phase 3 wins for its BTK inhibitor in multiple sclerosisnews2025-11-10T12:30:39+00:00November 10th, 2025|Endpoints News|
#AHA25: Ionis claims curative potential for Tryngolza in severe triglyceride diseasenews2025-11-10T12:03:22+00:00November 10th, 2025|Endpoints News|
